AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 14 of 14.
Apr 2008
3 Apr · Board meeting
Meeting on 28 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Feb 2008
25 Feb · Meeting
Board of directors at its meeting held on February 25, 2008 decided to transfer Rs.61.45 million to General Reserves. The Board has also recommended declaration of Dividend of Rs.15/- per Equity Share (Face Value Rs.2/- each), subject to the approval of the Shareholders at the ensuing Annual General Meeting. Further the Company has informed that the Annual General Meeting of the Company will be held on April 28, 2008. Further the Board has decided that the Register of Members and Share Transfer Books of the Company shall remain closed from April 16, 2008 to April 28, 2008 (both days inclusive).
Jan 2008
28 Jan · Board meeting
Inter-alia to consider and approve the audited annual accounts for the year ended December 31, 2007 and to recommend Dividend, if any.14 Jan · Allotment
At a meeting of the Board of Directors of the Company held today, i.e. January 12, 2008, the Board, pursuant to and in terms of the Scheme of Arrangement sanctioned by the Hon'ble High Court of Karnataka, Bangalore, and the subsequent approval of the Reserve Bank of India, have allotted 2,50,00,000 8% secured fully paid up redeemable debentures of Rs.25/- each aggregating Rs.62,50,00,000/- from the General Reserve of the Company, as Bonus Debentures, redeemable at the end of 12 months from the date of allotment, in the ratio of 1:1 i.e. One Bonus Debenture for every existing ordinary shares held by the shareholders of the Company as on 11th January 2008, being the record date fixed for the said purpose8 Jan · Results
Company would be submitting audited financial results for the financial year ended December 31, 2007, within the stipulated time limits.
Dec 2007
20 Dec · Corporate action
Consequent to the Order of the High Court of Karnataka sanctioning the Scheme under Section 391 of the Companies Act, 1956, the Company has now received the no-objection from the Reserve Bank of India (RBI) to the same. Accordingly, in terms of the Scheme, the Company would be initiating further steps for issuance of Bonus Debentures aggregating to Rs.62.50 crores, in the ratio of one debenture of the face value of Rs.25/- each for every equity share held by the shareholders as on the Record Date, redeemable at the end of 12 months from the date of allotment. The Company has fixed Friday, January 11, 2008, as the Record Date for determining the entitlement of shareholders to receive the Bonus Debentures
Oct 2007
5 Oct · Board meeting
Meeting on 26 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
26 Jul · Business
At a meeting of the Board of Directors held on July 26, 2007 the Board - a) Took note of the resignation of Mr Ruud Dobber and Dr Henrik Nistrup Madsen as Directors from the Board of the Company w.e.f. July 26, 2007. b) Approved the appointment of Mr. Graham Baker and Mr. Bhasker Iyer as Directors in the casual vacancy caused by the resignations of Mr Ruud Dobber and Dr Henrik Nistrup Madsen, respectively, w.e.f. July 26, 2007. Further, at the said meeting, the Board also noted that the Hon'ble High Court of Karnataka, Bangalore, has passed an order approving the Scheme of Arrangement between the Company and its shareholders for issue of secured fully paid-up redeemable non-convertible bonus debentures from the Company's General Reserve; though a certified copy of the same is yet to be received. The Board further noted that the Company would initiate further steps on receipt of the certified copy and such further approvals as may be necessary for making the Scheme effective.5 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended June 30, 2007.
Jun 2007
12 Jun · Miscellaneous
Abstract of the terms of Agreement and Memorandum of Concern or Interest of Director under Section 302 of the Companies Act, 1956, which has been despatched to all shareholders, in connection with the appointment of Mr. Anandh Balasundaram as Managing Director of the Company with effect from June 1, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
30 May · Meeting
Proceedings of the Annual General Meeting of the Company held on April 30, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 May · Management
At a Meeting of the Board of Directors held today i.e. May 21, 2007, the board has noted/approved the following: a) Consequent to the transfer of Mr Bhasker V Iyer, Managing Director, to a regional role in AstraZeneca as the Area vice President- South East Asia and India, with effect from June 1, 2007, he would be stepping down as Managing Director of the Company from end of the business hours on May 31, 2007 and further in terms of his appointment, Mr Bhaskar V. Iyer would ipso facto cease to be a Director of the Company from that date; b)Appointment of Mr Anandh Balasundaram as an Additional Director of the Company, with effect from June 1, 2007 ; and c) Appointment of Mr Anandh Balasundaram as the Managing Director of the Company in the place of Mr. Bhaskar V. Iyer, with effect from June 1, 2007, for a period of five years, subject to approval of the Shareholders of the Company at the next General Meeting of the Company
Apr 2007
10 Apr · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the first quarter ended 31st March, 2007.
Mar 2007
27 Mar · Symbol Change
Members of the Exchange are hereby informed that the trading symbol of AstraZeneca Pharma India Limited shall be changed from ASTRAIDL to ASTRAZEN w.e.f. April 10, 2007.19 Mar · Dividend
At the Meeting held today i.e. 17th march, 2007 the Board of Directors of the Company have inter-alia transacted/approved the following: (1) The Board of Directors revoked the dividend of Rs.12/- per equity share (face value of Rs. 2/- each), recommended earlier at its meeting held on February 23, 2007. (2) The Board has declared an Interim Dividend of Rs.12/- per equity share (face value of Rs. 2/- each), for the year ended December 31, 2006. As informed earlier, March 24, 2007 has been fixed as the Record Date for the purpose of payment of Interim Dividend. (3) Revised Audited Accounts for the year ended December 31, 2006, after necessary changes as to revocation of recommended dividend and payment of Interim Dividend as above, was approved by the Board. (4) The Register of Members and Share Transfer Books of the Company shall remain closed from 27th to 30th April 2007 (both days inclusive) for the ensuing Annual General Meeting scheduled on April 30, 200712 Mar · Management
At the Meeting of the Board of Directors held today i.e., 23.02.2007 (afternoon), Mr Ruud Dobber has been appointed as a Director of the Company9 Mar · Board meeting
To inter-alia consider the following business: 1) To consider revocation of recommended Dividend for the year ended December 31, 2006. 2) To consider payment of Interim Dividend for the year ended December 31, 2006, for which a Record Date of March 24, 2007 has been fixed. 3) To revise the Book Closure Dates fixed for the ensuing Annual General Meeting (AGM) scheduled on April 30, 2007 from April 23, 2007 - April 30, 2007 to April 27, 2007 to April 30, 2007 (both days inclusive). 4) To consider the approval of the revised Audited Accounts for the financial year ended December 31, 2006, after incorporating necessary changes as to the revocation of recommended dividend and payment of Interim Dividend for period ended December 31, 2006 and to make consequential changes in the Notice for the AGM and the Directors' Report.
Feb 2007
23 Feb · Meeting
Board at its meeting held on February 23,2007 approved the audited accounts for the year ended December 31, 2006 and decided to transfer Rs.50 million to General Reserves. The Board has also recommended declaration of Dividend of Rs.12/- per equity share (Face Value Rs.2/- each), subject to the approval of the shareholders at the ensuing Annual General Meeting. Further, the Annual General Meeting of the Company will be held on April 30,2007. The Board has also decided that the Register of Members and Share Transfer Books of the Company shall remain closed from April 23,2007 to April 30,2007 (both days inclusive).2 Feb · Board meeting
Inter-alia to consider and approve the audited annual accounts for the year ended 31st December, 2006 and to recommend Dividend, if any.
Jan 2007
9 Jan · Management
Mr. Andrew Howden has resigned as Director from the Board of the Company, effective from the close of 27th November, 20064 Jan · Management
Mr. N. R. Srinivasan who has joined the Company as Vice President - Legal & Company Secretary in December 2006 shall be the Compliance Officer pursuant to the Listing Agreement. Name of the Compliance Officer: N. R. Srinivasan. Phone: 080-23622021 - 27, Extn.409. Direct: 080-23622034. Fax: 080-23622044. E-mail ID: [email protected]. Registered Office Address: AstraZeneca Pharma India Limited, Off Bellary Road, Hebbal, Bangalore 560 024. Correspondence Address: -do-.